ATE429910T1 - Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen - Google Patents

Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen

Info

Publication number
ATE429910T1
ATE429910T1 AT06291548T AT06291548T ATE429910T1 AT E429910 T1 ATE429910 T1 AT E429910T1 AT 06291548 T AT06291548 T AT 06291548T AT 06291548 T AT06291548 T AT 06291548T AT E429910 T1 ATE429910 T1 AT E429910T1
Authority
AT
Austria
Prior art keywords
treatment
containing chlorine
derivatives containing
prion diseases
guanabenz derivatives
Prior art date
Application number
AT06291548T
Other languages
English (en)
Inventor
Marc Blondel
Stephane Bach
Didier Vilette
Vincent Beringue
Deborah Tribouillard
Original Assignee
Centre Nat Rech Scient
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Agronomique Inst Nat Rech filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE429910T1 publication Critical patent/ATE429910T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06291548T 2006-10-04 2006-10-04 Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen ATE429910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291548A EP1908465B1 (de) 2006-10-04 2006-10-04 Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen

Publications (1)

Publication Number Publication Date
ATE429910T1 true ATE429910T1 (de) 2009-05-15

Family

ID=37836911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06291548T ATE429910T1 (de) 2006-10-04 2006-10-04 Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen

Country Status (7)

Country Link
US (1) US20110251428A1 (de)
EP (2) EP1908465B1 (de)
JP (1) JP5186503B2 (de)
AT (1) ATE429910T1 (de)
CA (1) CA2664959A1 (de)
DE (1) DE602006006578D1 (de)
WO (1) WO2008041134A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
DK3280404T3 (da) 2015-04-08 2021-11-08 Res & Innovation Uk Fremgangsmåder til valg af phosphatase-selektive og ikke-selektive phosphatasehæmmere
EP3529237A1 (de) 2016-10-18 2019-08-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Naturproduktderivate zur hemmung von zellularer nekroptose, ferroptose und oxytose
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
WO2019215470A1 (en) 2018-05-09 2019-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975533A (en) * 1970-04-29 1976-08-17 Shell Oil Company Therapeutic agents
US3816531A (en) * 1970-07-01 1974-06-11 American Home Prod (2,6-disubstituted benzylidene)amino guanidines and related compounds
US6413962B1 (en) * 1988-05-02 2002-07-02 N. Eric Naftchi Guanidino compounds effective as anesthetics
AU5636300A (en) * 1999-06-25 2001-01-31 Avicena Group, Inc. Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
FR2846009B1 (fr) * 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
ES2328033T3 (es) * 2002-10-18 2009-11-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulacion de la actividad quinasa s6 para el tratamiento de la obesidad.
FR2893844B1 (fr) * 2005-11-28 2008-02-01 Centre Nat Rech Scient Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1908464A1 (de) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Verwendung von Chlorine-Guanabenz-Deriaten zur Behandlung von Polyglutaminexpansionskrankheiten

Also Published As

Publication number Publication date
CA2664959A1 (en) 2008-04-10
US20110251428A1 (en) 2011-10-13
EP1908465B1 (de) 2009-04-29
WO2008041134A2 (en) 2008-04-10
EP1908465A1 (de) 2008-04-09
EP2076253A2 (de) 2009-07-08
JP2010505815A (ja) 2010-02-25
DE602006006578D1 (de) 2009-06-10
WO2008041134A3 (en) 2008-06-19
JP5186503B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
EA201000050A1 (ru) Замещенные бициклолактамные соединения
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ATE517882T1 (de) Chinolinderivate
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
MA32505B1 (fr) 5-alcynyl-pyrimidines
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
WO2008041134A3 (en) Use of chlorine guanabenz derivatives for treating prion-based diseases
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EA200801425A1 (ru) Диазепиноны
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties